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Abstract
Fibromyalgia (FM) is today a serious public health issue. Tested treatments have shown limited efficacy. Oxidative stress probably
interacting with the glutamatergic / gamma - Aminobutyric acid balance may play a role. Antidepressants improve sleep and
mood especially those with double action on serotonin and norepinephrine, but these are also those with a greater risk of manic
switch considering the high frequency of comorbidity with bipolar disorders. This narrative review tries to evaluate, on the basis
of in vitro and animal studies, the potential utility in fibromyalgia of Hypericum Scruglii, an endemic species peculiar to the island
of Sardinia. The studies that have verified the antidepressant efficacy of Hypericum Perforatum and the first attempts of its use
in fibromyalgia are reported as well as the studies that found the phloroglucinol derivatives from Hypericum longistylum (well-
known in traditonal Chinese medicine) that facilitate the differentiation of neural progenitor cells, and increase the efficiency of
differentiation into serotonergic neurons. The advantage of Hypericum Scruglii may be represented by the anti-oxidant potential
revealed to be greater than in other species of the same genus. The paper also describes new approaches to improving the oral
bioavailability of very poor water-soluble molecules of hypericum extracts.
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Introduction
Fibromyalgia (FM) is a central sensitization syndrome with
around 3% of prevalence in western societies, especially fre-
quent in women [1]. The best-known symptom is chronic
widespread pain; other syndromes such as fatigue, anxiety,
mood disorders, and dysregulation of biological rhythms with
sleep disturbances frequently accompanied by pain [2]. FM
worsens the quality of life of people affected, and in cases with
comorbid mood disorders the worsening is so high as to be
similar to a chronic severe impairing disease such as Multiple
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Sclerosis [1]. The high frequency of the disorder and its high
disabling power also make it a serious public health issue. Tested
treatments have shown limited efficacy [1].
Oxidative stress might play a role in the pathophysiology of
FM by enhancing excitatory and decreasing inhibitory neuro-
transmission [3]. In fact, studies using multiple functional mag-
netic resonance imaging (fMRI) have shown enhanced gluta-
matergic neurotransmission in the brain insula to be associate
with high pain symptoms in people with FM [4]. Glutamater-
gic neurotransmission appears in fact to be a key point of cen-
tral sensitization [4]. Conversely, a diminished inhibitory neu-
rotransmission resulting from lower concentrations of GABA
within the right anterior insula was found in women with FM [5].
It has been demonstrated that some dietary elements protect
people with FM against oxidative stress and also improve func-
tional capacity and psychological status, probably interacting
with the glutamatergic/GABA balance [6].
Antidepressants have been found efficacious in treating some
of the syndrome components of fibromyalgia (particularly pain,
mood and sleep disturbances). Fibromyalgia has a close associ-
ation with bipolar disorder and the use of powerful antidepres-
sants can seriously increase the risk of manic switch [7]. This
is probably the reason why antidepressants do not change long-
term outcome indicators of remission [8].
The mechanism of action of antidepressants in fibromyalgia
is still unknown, mood stabilization and improved sleep have
been hypothesized as playing a role. However the most pow-
erful antidepressants in the treatment of fibromyalgia are those
that have a double action in strengthening serotonin and nore-
pinephrine, but these are also those with greater risk of manic
switch [2].
Material and Methods
This narrative review tries to evaluate, on the basis of in vitro and
animal studies, the potential utility in fibromyalgia of Hypericum
Scruglii, an endemic species peculiar to the island of Sardinia.
Results and Discussion
Hypericum in depressive disorders
Hypercum L is a genus inside the family Hypericaceae of flow-
ering plants whose most known element in the medical field is
Hypericum perforatum. A consistent body of studies, based on
randomized controlled trials and meta-analyzes, supports the ef-
ficacy and safety of Hypericum perforatum L. (also known as St.
John’s wort) and its active ingredients, hypericin and hyperforin,
in depressive disorders similar to those of tricyclic antidepres-
sants and selective serotonin reuptake inhibitors, but with fewer
and milder side effects [9] and with significantly lower discon-
tinuation/dropout [10].
Moreover, Hypericum perforatum extract is rich in active an-
tioxidant flavonoids such as quercetin and rutin and, like these, is
expected to reduce oxidative stress and increase gene expression
of antioxidant enzymes [11, 12].
Hypericum is also known to interact at the pharmacokinetics
levelwith many drugs, thus caution is recommended for patients
on medication in the use of high dosages of active principles of
the plant. However, its use in depression has proved useful even
at low doses as a food supplement, therefore with little potential
for interaction with other drugs [9].
Recently, a Chinese study has found that one of the phloroglu-
cinol derivatives from Hypericum longistylum Oliv., well known
in traditional Chinese medicine, facilitated the differentiation of
neural progenitor cells and increased the efficiency of differen-
tiation into serotonergic neurons. In possible relationship with
these effects on neurogenesis, this compound was shown to im-
prove the behavior of mice placed in a stressful environment and
reduce signs of depression [13].
Hypericum scruglii as a potential tool in the
treatment of fibromyalgia
The antidepressant properties of the Hypericum genus, together
with the possible action on the serotonergic system involved in
pain circuits have indicated a potential use of this plant genus in
the treatment of fibromyalgia [9]. This was also suggested ow-
ing to the low profile of side effects and, more specifically, since
[no virgola] at the dosages used in antidepressant therapy there
are few descriptions of inductions of manic states. A recent re-
view of world literature found a total of 12 reports of cases of
people taking Hypericum perforatum for depression who had a
manic switch [14]. This is a very low figure considering that the
survey has been conducted on nearly 4,000 patients who took
derivatives or plant extracts. In addition, one case was a patient
who was treated with testosterone and a conventional selective
serotonin reuptake inhibitor antidepressant, but continued to take
St John’s wort against medical advice [15]; another was a case
of mania induced by higher-than-usual assumed doses of Hyper-
icum perforatum [16] and in general, a review of all the cases
described show that the average dosages used were higher than
usual. This aspect is relevant considering the close association
of fibromyalgia with bipolar disorder. The risk of manic switch
in fibromyalgia should always be properly assessed, monitored
and not underestimated.
In addition, in vivo studies have found the efficacy of low
doses of the extract of H. perforatum (0.3% hypericins; 3-5%
hyperforins) in inducing analgesia in both acute and chronic hy-
peralgesic conditons and improving opioid action [17]. Clinical
studies (carried out both in traditional and conventional medical
frameworks) highlighted dental pain conditions as a usual appli-
cation [17, 18]. Analgesia appears at low doses, thus minimizing
the risk of herbal-drug interactions produced by hyperforin, a po-
tent inducer of Cytochromes P450 enzymes (CYPs) [18] but also
minimizing the manic switch in people with co-morbid bipolar
disorders.
Hypericum scruglii is an endemic species distributed in
central-east and southeast Sardinia, in particular in the Sarci-
dano, Barbagia of Seulo, Ogliastra and Quirra subregions. It
is generally linked to calcareous substrates such as limestone,
conglomerate, travertine, sandstone and marl, where it grows
exclusively on damp soil near freshwater springs or streams.
Occasionally, it is found in pools. It is especially linked to
subalkaline and alkaline soils, not much developed from the
pedogenetic point of view [19]. This plant has characteristics
that could make it a privileged target in fibromyalgia studies:
in vitro and in vivo this species has been seen to have a greater
anti-ossidant potential than other Hypericum species, including
Hypericum perforatum [20].
In addition to the recognized properties of all member of the
Hypericaceae family, this aspect is particularly relevant; Hyper-
icum scruglii shows in fact a specific feature that could act with
different steps on the pathogenesis of fibromyalgia and on sev-
eral phases of the short circuits that cause relapses [2].
These can be summarized as follows:
1) The specific antioxidant effect can act on the glutamate /
Gaba balance
2) The anti-pain / analgesic effect can interact with the symp-
tom described as the most disabling
3) The serotoninergic effect may regulate sleep
4) The antidepressant effect can act, by improving basic
mood, on the "catastrophic" cognitive cascade described by cog-
nitive behavioral psychologists as a consequence of hypersen-
sitivity to pain that paradoxically increases the likelihood of
chronicity [2].
Availability of new approaches to improving the oral
bioavailability of very poor water-soluble molecules
of hypericum extracts.
An innovative approach to modulating pharmacokinetic and
pharmacodynamic activity of extracts by I improving their
bioavailability is the use of nanocarriers. Nanomedicine is
widely acclaimed as circumventing the obstacles of poor phar-
macokinetics, especially in oral administration. However, the
use of these systems has traditionally been confined to opti-
mization of synthetic drug formulations and only in the last
decade have their possible challenges been explored to improve
pharmacokinetics of natural active molecules or extracts [21]
. Among the different nanocarriers, modified liposomes have
shown a good ability to improve the local and systemic efficacy
of natural molecules or extracts [22, 23]. These formulations
can improve the oral bioavailability of very poor water-soluble
molecules such as hyperforin, hypericin, quercetin and rutin,
which are present in the hypericum extracts. In a previous study,
cyclodextrin and liposomal preparations were investigated for
improving delivery of hypericin through the intestinal epithe-
lium by passive transcellular diffusion.
The efficient extraction of bioactive phytocomplex from H.
scruglii and its suitable nanoformulation in ad hoc modified li-
posomes should improve the efficacy of the extract in counter-
acting FM symptoms and the compliance of patients in reducing
the dose and the number of required administrations.
Conclusions
In vivo and in vitro studies in animals appear to indicate that
H. scruglii may enhance the therapeutic effects on fibromyalgia
that other members of the Hypericaceae family have shown in
preliminary clinical studies on fibromyalgia.
Phase 1 and 2 studies would be needed to prepare random-
ized controlled trials on the efficacy of H. scruglii extracts in
fibromyalgia. The serious public health issues posed by this dis-
order, for which no therapy is known, reinforces the need for this
kind of study.
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